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Background: Pain related to ultraviolet B radiation (UVR) induced sunburn is an established, 
simple, acute pain model. One of the major criticisms is related to the potential dermal adverse 
events caused by the UVR exposure. This study tried to validate the model for oral and topical 
drugs and to define the minimum required UVR exposure.
Methods: This subject- and observer-blinded, placebo-controlled, crossover study evaluated 
600 mg oral ibuprofen (IB) and topical hydrocortisone-21-acetate (HC) twice daily (bid) in 
24 healthy volunteers. Treatment started immediately after irradiation and again at 12 hours, 
24 hours, and 36 hours post-UVR. Assessment of hyperalgesia to heat and signs of inflammation 
(erythema, skin temperature) for all areas was performed after UVR and again at 6, 12, 24, 36, 
and 48 hours. Subjects returned within 4–11 days to the study site for the second period of the 
study. As in the first period, subjects received HC at one side and topical placebo on the other 
side, but oral treatment was crossed-over.
Results: The primary analysis failed to show the expected superiority of the IB-group vs the 
placebo group in period 1 of the study. Evaluating period 2 alone clearly showed the expected 
treatment effects of IB for erythema and heat pain threshold. The results were less pronounced 
for skin temperature. In contrast to IB vs oral placebo, there were no differences in treatment 
response between HC and topical placebo. UVR at all dosages induced profound erythema and 
reduction of heat pain threshold without causing blisters or other unexpected discomfort to the 
subjects. The changes were almost linear between 1 and 2 minimal erythema doses (MED), 
whereas the change from 2 to 3 MED was less pronounced.
Conclusion: Use of 2 MED in upcoming studies seems to be reasonable to limit subjects’ 
UVB exposure. The following procedural changes are suggested:
•  Intensified training sessions before randomization to treatment
•  Increase in sample size if they are crossover studies
•  Simplification in design (either oral or topical treatment)
Keywords: ibuprofen, hydrocortisone-21-acetate, pain, inflammation, UV radiation, 
validation
Introduction
Pain related to UVR-induced sunburn is an established, simple, acute pain model.1,2 
One of the major criticisms related to this model is the potential dermal adverse events 
caused by the UVR exposure.
The main cause of sunburn in human skin is UVR of wavelengths from 290 nm to 
320 nm. Erythema begins to develop approximately 3–5 hours after UVR exposure, 
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reaches a maximum at 12–24 hours, and fades over 72 hours.3 
Skin UVR is followed by a series of biochemical and immu-
nologic events that cause inflammation. Histologically, it is 
characterized by dyskeratotic and vacuolated keratinocytes 
known as sunburn cells, mild epidermal spongiosis, depletion 
of Langerhans cells, dermal edema, endothelial cell enlarge-
ment, and later a neutrophilic dermal infiltrate.4 Some of the 
substances that are thought to be inflammatory mediators 
include prostaglandins, lipoxygenase products, cytokines 
(eg, tumor necrosis factor-alpha), adhesion molecules, reac-
tive oxygen radicals, and mast cell-derived mediators, such 
as histamine, and substance P.5
Inflammation and pain related to UVR-induced sunburn 
was introduced by Bickel et al1 for the evaluation of anal-
gesic effects and is now more broadly used as a simple pain 
model using three times the minimal erythema dose (MED) 
to evaluate the efficacy of NSAIDs but can also be used for 
corticosteroids.6–8
The study was designed to establish a test model for thera-
peutic interventions using UVR-induced pain and inflamma-
tion as a surrogate and to define the minimum required UVR 
exposure. Those effects were studied at various degrees of 
severity of UVR-induced inflammation and pain (1–3 times 
MED). For reference in future studies, this study evaluated 
and compared the effects of an orally administered NSAID 
(ibuprofen) and a topical corticosteroid with known effects 
on UVR-induced pain and inflammation. Subjects were 
randomized to receive ibuprofen (IB) or oral placebo dur-
ing the first period and vice versa during the second period 
(crossover design).
Methods
This was a single-center, randomized, subject- and observer-
blinded, placebo-controlled, crossover study of the effect 
of oral IB and topical hydrocortisone-21-acetate (HC) in 
healthy volunteers, conducted in two periods, using an 
intra-individual comparison of application areas. The study 
was approved by the national authorities (BfArM) and the 
independent ethics committee of the Landesärztekammer 
Bayern.
subjects
Healthy subjects with a target age of 18–55 years and 
Fitzpatrick skin types I, II, or III9 who signed the informed 
consent were screened for study participation. Patients 
meeting any of the following exclusion criteria were not 
included into the trial: skin lesions; dermatological diseases 
or tattoo in the treatment areas; known hypersensitivity 
or allergy (  including photoallergy) to any ingredient of 
the study medication; history of photosensitivity disease; 
sunburn, excessive tan, uneven skin tones or blemishes 
of the test areas or use of tanning lamps or tanning beds 
within 3 months before enrolment; conditions or analgesic 
medication which might interfere with pain rating during 
the study; and contraindications and warnings listed in the 
summary of product information of IB. Systemic or topical 
drugs that might affect responses to UVR or interfere with 
responses to the investigational medical product includ-
ing corticosteroids, thiazides, tetracyclines, NSAIDs, and 
drugs with potential dermatologic adverse events defined 
by the respective summary of product characteristics (eg, 
tetracyclines, gyrase inhibitors) had to be washed out over 
a period of 5 times half-life, prior to the first irradiation, 
and were not taken throughout the study.
Subjects were also excluded if they showed poor 
repeatability of heat pain threshold determination in the 
training session.
Treatments
Immediately after irradiation, subjects were randomized 
to receive either IB (Ibuhexal®; Hexal AG, Holzkirchen, 
Germany) 600 mg film tablet (IB) or oral placebo. In addi-
tion to the oral medication, the test areas for topical treatment 
were randomized to receive either HC (Soventol® HydroCort 
0.25%, Medice Pharma GmbH, Iserlohn, Germany) or topi-
cal placebo 15 µL/cm2 applied to three treatment areas each, 
on one side of the back.
Medication was administered twice daily (bid) at 12-hour 
intervals during site visits.
Treatment allocation was crossed over in period 2. 
  Subjects who received IB in period 1 received oral placebo 
in period 2 and vice versa. Topical treatment was the same as 
in period 1 but new treatment areas on the back were selected 
(and irradiated) and side allocation was switched.
study procedures
Irradiation was performed using a UVB system (UV 109 B; 
Waldmann, Villingen-Schwenningen, Germany).   Irradiance 
was measured on each (protected) individual test area before 
irradiation using a broadband UVB detector connected to a 
radiometer (UV Meter for UV 21; Waldmann, Villingen-
Schwenningen, Germany). The number of test areas that were 
irradiated at one step was dependent on the homogeneity of 
the irradiance (±15% of 2.5 mW/cm² allowed).
To define the MED, skin areas with 2 cm diameter were 
irradiated with the following defined doses: 20, 50, 80, 110, 
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140, 170, 200, and 230 mJ/cm². Readout was   performed 
24 ± 2 hours after UVR under standardized lighting condi-
tions, using a 75 W blue light bulb. The individual MED 
  corresponded to the dose level inducing an erythema 
  assessment score of 2 on a 7-point categorical scale (mild 
erythema with clearly defined borders).
For the evaluation of effects on pain and inflammation, 
four skin areas (diameter of 2 cm) were defined on each side 
of the back (different from the areas of MED determination). 
One of the four areas on one side remained nonirradiated, 
one area on the contralateral side was irradiated with 3 MED 
but did not receive topical treatment. The other three areas 
were irradiated with 1, 2, or 3 MED, respectively, on both 
sides for topical treatment.
For the detection of heat pain threshold, heat stimuli were 
delivered to the skin from a thermode (9 × 9 mm; Somedic 
AB, Stockholm, Sweden) with feedback controlled by a 
thermocouple mounted in the surface of this thermode. The 
upper range of the thermode was limited to 52°C to protect 
from skin damage. The temperature of the thermode was 
slowly increased by 0.5°C per second from an adapting 
temperature of 32°C. Subjects were instructed to terminate 
heating by pressing a button as soon as the heat produced 
by the thermode became painful. The heat pain threshold 
was evaluated with a series of five consecutive determina-
tions for each test area. For determination of the heat pain 
threshold temperature, the mean of the last three values was 
calculated.
In order to accustom subjects to the experimental equip-
ment and procedures, they underwent a training session before 
randomization to treatment. Heat pain thresholds were mea-
sured at areas used for MED reading and nonirradiated control 
areas. Ten assessments (five on one normal skin area and five on 
the test area of the area that was rated 1 MED) were   performed. 
Upon poor repeatability of thresholds (last three values 
for each test area must not be more than 3°C apart) subjects 
were excluded from the study. Data acquired in the training 
session were recorded but not included in the analysis.
The degree of erythema was evaluated visually using 
a 7-point categorical scale (0 = no erythema response, 
6 = intense erythema with sharp borders and edema).
Skin temperature at the test areas was evaluated as a 
surrogate marker for an inflammatory response using an 
infrared thermometer (PCE-FIT 10, 149 × 77 × 43 mm; 
PCE Group, Meschede, Germany). Measurement distance 
between thermometer and skin was 5 cm. Measurements were 
done in duplicate at ambient temperature after 15 minutes 
of adaptation.
During both periods of the study, rating was done 
immediately after UVR but before the first application 
of medication. Subsequent ratings for all test areas were 
performed before application of the drug at 6 hours and 
at 12 hours, 24 hours, and 36 hours, and then again at 
48 hours/final visit.
Efficacy parameters were always evaluated in the follow-
ing sequence: (1) degree of erythema; (2) skin temperature; 
(3) hyperalgesia to heat.
statistics
The sample size of 24 was chosen with reference to Sycha 
et al and our own previous data.2,7 For the evaluation of the 
study endpoints a two-period crossover-analysis Wilcoxon 
test (2-sided test for difference) for sums, differences, and 
crossover differences was performed.9
Due to the fact that the results of the primary efficacy 
analysis showed potential carryover effects, separate analyses 
were performed using nonparametric testing.
The analysis was performed using the intention-to-treat 
population.
Results
For study participation, 28 subjects were screened. Four of 
the subjects screened were not included. The reasons for 
screening failure were: three subjects showed poor repeat-
ability of heat pain threshold determination in the training 
session (exclusion criterion) and one subject withdrew 
informed consent. As planned, 24 subjects were randomized. 
All subjects completed the study; there were no dropouts.
The analysis of the primary endpoint (hyperalgesia to 
heat) comparing the IB group with the oral placebo group, 
using the area irradiated with 3 MED and without topical 
treatment, showed no statistically significant treatment 
effects (P = 0.4502, see Table 1). However, in contrast to the 
assumptions made during preparation of the study, significant 
carryover effects could be demonstrated for the comparison 
of period 1 and 2 (P = 0.0386). Similarly, the comparison of 
Table  1  Descriptive  statistics  (mean  ±  standard  deviation)  and 
results  of  the  two-period  crossover-analysis  of  treatment  and 
carryover effects comparing ibuprofen to placebo (3 MED) 
Parameter Ibuprofen Placebo Treatment Carryover
HPT 270.8 ± 15.8 267.2 ± 17.1 ns P = 0.0386
Erythema   14.7 ± 2.0   16.5 ± 1.8 P = 0.0233 ns
Temperature 202.2 ± 4.1 203.3 ± 3.3 ns P = 0.0052
Note: Evaluation of sum scores HPT, erythema, and skin temperature.
Abbreviations: MED, minimal erythema dose; HPT, heat pain threshold; ns, not 
significant.
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the topical products (HC vs placebo) at 3 MED showed no 
statistical significant treatment effects, but showed   carryover 
effects. For erythema, statistically significant treatment 
effects could be shown (P = 0.0233) without a significant 
carryover effect (P = 0.1574), while skin temperature showed 
pronounced carryover effects (P = 0.0052) without evidence 
of treatment effects.
Due to the fact that the primary analysis showed sub-
stantial carryover effects, separate analyses were performed 
for the first and the second period of the study with a focus 
on the comparison of heat pain threshold and erythema of 
the IB group.
IB failed to show significant effects on all parameters in 
period 1 of the study. In contrast, during period 2 the expected 
treatment effects could be shown for IB as compared to 
placebo (see Table 2).
A detailed analysis for the various treatment groups and 
MED levels within period 2 showed at 3 MED that IB is 
superior to placebo for both erythema and hyperalgesia to 
heat (P = 0.0944 and P = 0.0513, respectively) with a large 
effect size (Mann–Whitney estimator = 0.843 and 0.7686, 
respectively). Also, skin temperature showed a trend in 
favor of IB. The differences were even more pronounced 
at 2 MED (erythema: P = 0.0044, hyperalgesia to heat: 
P = 0.0357, skin temperature: P = 0.0037). At 1 MED, the 
differences were again statistically significant in favor of 
IB for erythema and hyperalgesia, but not for skin tempera-
ture (erythema: P = 0.0094, hyperalgesia: P = 0.0430, skin 
temperature: P = 0.396).
There were no differences in treatment response between 
HC and placebo for any strength of irradiation (1–3 MED) 
and any criteria observed (erythema, hyperalgesia, skin 
temperature).
The kinetics of the UVR-induced changes indicated a 
radiation dose-related decrease of the heat pain threshold 
starting 6 hours after UV exposure (see Figure 1A). The 
changes are most pronounced 24–36 hours after UVR and 
start returning to baseline levels at 48 hours post-UVR. For 
erythema, 1 and 2 MED produced a profound increase in the 
erythema score. The scoring did not increase substantially 
further for 3 MED as compared to 2 MED (Figure 1B). 
Skin temperature shows a circadian rhythm with higher 
temperature in the evening (12 hours, 36 hours) and UVR 
dose-dependent increase for 1 and 2 MED with again no 
substantial further increase for 3 MED (Figure 2C).
Since 3 MED did not seem to provide improved assay 
sensitivity as compared to 2 MED, the kinetics of UVR-
induced changes between IB, HC, and placebo were com-
pared at 2 MED.
IB produced profound treatment-induced improvements 
for all outcome criteria (see Figure 2A–C) with differences 
least pronounced for skin temperature. HC failed to show a 
differentiation from placebo for all criteria.
Sixteen adverse effects (AE) were observed in 12 (50%) 
of the 24 subjects treated. All AEs were of mild intensity. 
Only one AE (from 16) was judged as related to IMP: 
“  erythema at test area”. No severe AEs occurred.
No clinically relevant changes in laboratory parameters 
or vital signs were observed.
All IMP were very well tolerated. The study proce-
dures (UVR) did not cause unexpected discomfort to the 
subjects.
Table 2 Descriptive statistics (mean ± standard deviation) and results of Wilcoxon–Mann–Whitney analysis comparing ibuprofen to 
placebo (P value 1) and hydrocortisone to placebo (P value 2) at various MED levels for period 2
Parameter MED level Placebo Ibuprofen P value 1 Hydrocortisone P value 2
HPT 0 289.4 ± 11.8
1 274.5 ± 16.7 287.4 ± 8.5 0.0430 278.0 ± 13.8 .0.1
2 268.4 ± 18.2 282.0 ± 11.2 0.0357 268.1 ± 17.9 .0.1
3 264.7 ± 14.4 278.9 ± 13.1 0.0513 265.2 ± 20.8 .0.1
Erythema 0 0
1 10.3 ± 2.5     6.3 ± 2.9 0.0094   10.4 ± 2.9 .0.1
2 16.1 ± 2.1   12.2 ± 2.7 0.0044   16.0 ± 2.3 .0.1
3 17.3 ± 1.9   15.0 ± 2.3 0.0944   17.8 ± 1.9 .0.1
Temperature 0 199.4 ± 3.6
1 201.9 ± 3.7 200.0 ± 3.8 .0.1 203.0 ± 2.6 .0.1
2 204.4 ± 2.9 200.2 ± 3.7 0.0037 204.0 ± 2.9 .0.1
3 205.0 ± 2.4 201.7 ± 3.8 0.0716 204.8 ± 3.0 .0.1
Note: Evaluation of sum scores for heat pain threshold (HPT), erythema, and skin temperature.
Abbreviations: MED, minimal erythema dose; HPT, heat pain threshold; ns, not significant.
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Discussion
The analysis of the primary endpoint (hyperalgesia to 
heat) for the crossover design failed to show the expected 
superiority of the IB group vs the OP group as reported 
by others.2 In line with the study of Sycha et al,2 we found 
substantial differences between study periods. But in con-
trast to this study, our design had more complexity due to 
the additional topical treatment. This may be one explana-
tion for the lack of statistical significance for the primary 
hypothesis. Substantial differences in heat pain threshold 
evaluations between the first and follow-up session were 
also reported by Yarnitzky et al.10 Reasons given for the 
bias include practice effects. One of the important practice 
effects is training-related change in reaction times which 
are of   particular importance to the evaluation of heat pain 
threshold. But practice effects may not only involve the 
subjects but also the study personnel. Since evaluating 
period 2 alone clearly showed the expected pharmacologi-
cal effects, we suggest the following changes for follow-up 
studies: intensified training sessions before randomization 
to treatment; increase in sample size for crossover studies; 
simplification in design (either oral or topical treatment); 
use of a larger thermode (eg, 18 × 18 mm) to recruit more 
pain receptors for more consistent results.
If period 2 was analyzed alone, the predicted effects 
of IB were shown consistently across different degrees 
of inflammation (1–3 MED) for erythema and heat pain 
threshold. The results were less pronounced for skin 
temperature.
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Figure 1 Kinetics of UVR-induced changes (Mean ± sEM) of heat pain threshold (A), 
erythema (B) and skin temperature (C) for nonirradiated skin (0 MED) and increasing 
levels of UVR (1–3 MED). 
Abbreviations: UVR, ultraviolet B radiation; sEM, standard error in the mean; 
MED, minimal erythema dose.
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Figure 2 Kinetics of UVR-induced changes (Mean ± sEM) of heat pain threshold (A), 
erythema (B) and skin temperature for skin irradiated at 2 MED and treated with 
ibuprofen or hydrocortisone as compared to nonirradiated skin (0 MED).
Abbreviations: UVR, ultraviolet B radiation; sEM, standard error in the mean; 
MED, minimal erythema dose.
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In contrast to IB, there were no differences in treatment 
response between HC and PG for any strength of irradiation 
(1–3 MED) and any criteria observed (erythema,   hyperalgesia, 
skin temperature). There is contradictory evidence for the 
effects of corticosteroids for the treatment of UVR-induced 
skin reactions. Mid- or high-potency steroids showed reduction 
of acute sunburn symptoms when applied before UVR exposure 
but not when applied 6 hours or later after UVR exposure.6,8 
The lack of effects seen in this study may either be related to 
the fact that the first treatment was applied immediately after 
UVB radiation and not before, or because of the low potency 
of hydrocortisone per se or as used in this study. The evalua-
tion of low potency steroids may also require larger sample   
sizes.11
UVR at up to 3 MED induced profound reduction in 
heat pain threshold, increase of skin temperature and caused 
profound erythema. The changes were almost linear between 
1 and 2 MED, whereas the change from 2 to 3 MED was less 
pronounced, in particular for erythema and skin temperature. 
This is in line with the findings of Harrison et al.12 One of 
the reasons claimed for this observation is first evidence of 
edematous changes at 3 MED. Jocher et al suggested the 
use of 1.5 MED on the basis of just evaluating the effect on 
erythema.11 Since we found similar pharmacological effects 
between 2 and 3 MED, use of 2 MED in upcoming studies 
seems to be reasonable to limit UVB exposure to subjects. 
In order to allow precise determination of the UV dosages 
only subjects with skin type I–III according to Fitzpat-
rick13 were enrolled and individual sensitivity to UV was   
determined.
A variety of experimental pain models for the evalu-
ation of NSAID efficacy involving healthy subjects have 
been reported.1–14 Nevertheless, UVR-induced pain models 
offer several advantages over other pain models in healthy 
volunteers. Inflammation and hyperalgesia are constant 
for several hours, representing an advantage not only over 
  freezing, burning, or chemically induced inflammation, 
but also over painful clinical disorders which are often 
of   episodic nature. UVR models are therefore able to 
test the effects of drugs with low variability. In addition, 
the upper heating limit of the thermode can be defined 
in order to avoid skin damage, and the discontinuation 
of the heating procedure is under the subject’s control 
at any time. Hence, compared with freezing, burning, or 
chemically induced inflammation and hyperalgesia, UVR-
induced pain models should be better tolerated by the   
volunteers.
All study medications were very well tolerated. The study 
procedures (UVR) did not cause blisters or other unexpected 
discomfort to the subjects.
Conclusion
Use of 2 MED in upcoming studies seems to be reasonable 
to limit UVR exposure to subjects. The following proce-
dural changes are suggested: Intensified training sessions 
before randomization to treatment; increase in sample size 
for crossover studies; simplification in design (either oral or 
topical treatment).
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